12 Key Oncology Drug Launches Expected In 2022 – Hematological Malignancies

Aug 19 2021

• By Alexandra Shimmings

Listen to this article

In a series of articles, Scrip takes a look at some of the key novel products expected to reach the market in 2022 in a cross-section of therapy areas. Here, with input from Biomedtracker, are 12 new oncology products developed to treat hematological malignancies that, if successful at the regulators, are due to be launched for the first time next year.

Destruction of leukaemia cell, conceptual image. 3D illustration which can be used to illustrate blood cancer treatment — • Source: Shutterstock

The Paris-headquartered ERYTECH Pharma S.A. is looking to submit eryaspase to the US Food and Drug Administration in the fourth quarter for hypersensitive acute lymphoblastic leukemia (ALL). This represents a turnaround for the company which had originally filed the product for ALL in the EU before pulling the submission three years ago after deciding that solid tumors, particularly pancreatic cancer, represented the best way forward for the compound. (Also see "Erytech Pulls Graspa ALL Filing To Focus On Pancreatic Cancer" - Scrip, 25 June, 2018.)

Indeed, progress in pancreatic cancer is still on track, and this indication remains the primary focus for the product. Eryaspase...

More from New Products

Scrip-NewProducts (Premium-2): Top 12 Pharma Companies: Pfizer Tops The Leaderboard Again
Jun 14 2025
• By Nabil
The world’s biggest pharmaceutical companies mostly saw growth in 2024 but 2025 promises to be more of a mixed bag with headwinds including losses of exclusivity, Medicare Part D redesign and challenges in the Chinese market.
Innovent/GenFleet Score China’s First KRAS G12C Inhibitor Approval
Mar 10 2025
• By Dexter Jie Yan
The nod will help unlock a national market for the partners’ Dupert (fulzerasib) in which roughly 50,000 people are expected to be newly diagnosed with lung cancer harboring the KRAS G12C mutation in 2025. Meanwhile, two other homegrown rivals are also closing in on marketing clearances in China.
Cagrisema Leads The Charge For 2025
Mar 10 2025
• By Elizabeth Cairns
2030 sales forecasts for Novo’s obesity hope are an order of magnitude larger than its closest rival among 2025’s expected debutantes.
Small But Mitey: Tarsus To Amp Up Strong Xdemvy Launch
Mar 10 2025
• By Alexandra Shimmings
Tarsus Pharmaceuticals is putting more sales and marketing heft behind its novel eyelid disease therapy, Xdemvy, to capitalize on a solid start in a previously untapped market.

More from Scrip

sponsored
Sponsored by :
Clinical Trial Complexity Is Reshaping Evidence Collection Clinical trial innovation has historical
As clinical trials grow more complex, execution pressures are changing where and how evidence is collected.
EHA: Lilly’s Jaypirca Posts First Phase III Triplet Win In CLL While BTK Degraders Advance
Jul 15 2026
Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.
EHA: Lilly’s Jaypirca Posts First Phase III Triplet Win In CLL While BTK Degraders Advance - Clone
Jun 18 2026
Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.